⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101163 | 0.69 | — | — | |
| SCHEMBL27833417 | 0.67 | KMT2A (0.45) | — | |
| SCHEMBL2480336 | 0.67 | — | — | |
| SCHEMBL1101162 | 0.67 | — | — | |
| SCHEMBL2533959 | 0.67 | ALDH1A1 (0.38) | — | |
| SCHEMBL27702 | 0.67 | — | — | |
| SCHEMBL1493862 | 0.66 | TSHR (0.39) | — | |
| SCHEMBL7595015 | 0.65 | — | — | |
| SCHEMBL5477666 | 0.65 | — | — | |
| Ammonia Solution, Strong SCHEMBL15742962 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210598-B1 | Anticonvulsant amino acids for the treatment of pain | RES CORP TECHNOLOGIES INC (US) | 2013-09-18 | — | — | EP | claimed |
| EP-1695703-B1 | Anticonvulsant amino acids for the treatment of obsessive-compulsive neurosis | RES CORP TECHNOLOGIES INC (US) | 2010-08-11 | — | — | EP | claimed |
| EP-1486205-B1 | Use of anticonvulsant aminoacids for the treatment of migraine | RES CORP TECHNOLOGIES INC (US) | 2007-10-17 | — | — | EP | claimed |
| EP-1486206-B1 | Uses of anticonvulsant aminoacids for the treatment of bipolar disorders | RES CORP TECHNOLOGIES INC (US) | 2007-10-17 | — | — | EP | claimed |
| EP-1365787-B1 | USE OF AMINO ACID ANTICONVULSANTS FOR TREATMENT OF PAIN | RES CORP TECHNOLOGIES INC (US) | 2007-03-21 | — | — | EP | claimed |
| US-6806277-B2 | ANTIBACTERIAL AGENTS; HEMOPHILUS INFLUENZA; METICILLIN RESISTANT STAPHYLOCOCCUS AUREUS AS5155; STREPTOCOCCUS PNEUMONIAE 6254-01; ENTEROCOCCUS FAECIUM ATCC29212 OR H983401; MORAXELLA CATHARRHALIS IPA152 | AVENTIS, PHARMA S.A. (FR) | 2004-10-19 | — | — | US | claimed |
| US-20040058919-A1 | Quinolylpropylpiperidine derivatives, preparation process and intermediates, and compositions including them | AVENTIS PHARMA S.A. (FR) | 2004-03-25 | — | — | US | claimed |
| US-20070196335-A1 | Immune Modulation By Regulating Expression Of The \"Minor\" Gene In Immune Dendritic Cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-08-23 | — | — | US | disclosed |
| EP-1539734-B1 | PIPERIDINE QUINOLYL PROPYL DERIVATIVES AND USE THEREOF AS ANTIMICROBIAL AGENTS | NOVEXEL (FR) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005077048-A2 | IMMUNE MODULATION BY REGULATING EXPRESSION OF THE “MINOR” GENE IN IMMUNE DENDRITIC CELLS | THE JOHNS HOPKINS UNIVERSITY (US) | 2005-08-25 | — | — | WO | disclosed |
| EP-1539734-A1 | PIPERIDINE QUINOLYL PROPYL DERIVATIVES AND USE THEREOF AS ANTIMICROBIAL AGENTS | Aventis Pharma S.A. (FR) | 2005-06-15 | — | — | EP | disclosed |
| US-6806277-B2 | ANTIBACTERIAL AGENTS; HEMOPHILUS INFLUENZA; METICILLIN RESISTANT STAPHYLOCOCCUS AUREUS AS5155; STREPTOCOCCUS PNEUMONIAE 6254-01; ENTEROCOCCUS FAECIUM ATCC29212 OR H983401; MORAXELLA CATHARRHALIS IPA152 | AVENTIS, PHARMA S.A. (FR) | 2004-10-19 | — | — | US | disclosed |
| US-6806277-B2 | ANTIBACTERIAL AGENTS; HEMOPHILUS INFLUENZA; METICILLIN RESISTANT STAPHYLOCOCCUS AUREUS AS5155; STREPTOCOCCUS PNEUMONIAE 6254-01; ENTEROCOCCUS FAECIUM ATCC29212 OR H983401; MORAXELLA CATHARRHALIS IPA152 | AVENTIS, PHARMA S.A. (FR) | 2004-10-19 | — | — | US | disclosed |
| WO-2004011454-A3 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2004-04-08 | — | — | WO | disclosed |
| US-20040058919-A1 | Quinolylpropylpiperidine derivatives, preparation process and intermediates, and compositions including them | AVENTIS PHARMA S.A. (FR) | 2004-03-25 | — | — | US | disclosed |
| US-20040058919-A1 | Quinolylpropylpiperidine derivatives, preparation process and intermediates, and compositions including them | AVENTIS PHARMA S.A. (FR) | 2004-03-25 | — | — | US | disclosed |
| WO-2004024713-A1 | PIPERIDINE QUINOLYL PROPYL DERIVATIVES AND USE THEREOF AS ANTIMICROBIAL AGENTS | AVENTIS PHARMA S.A. (FR) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004011454-A2 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2004-02-05 | — | — | WO | disclosed |
| EP-0101411-A2 | Process for the chemical bond between a stabilising compound and a polymer | CIBA-GEIGY AG (CH) | 1984-02-22 | — | — | EP | disclosed |